BC Week In Review | Jan 26, 2018
Clinical News

Atara reports expanded access protocol data of tabelecleucel

Atara Biotherapeutics Inc. (NASDAQ:ATRA) reported data from a U.S. expanded access protocol study showing that IV tabelecleucel led to an objective response rate (ORR) of 83% among six patients with Rituxan rituximab-refractory Epstein-Barr virus (EBV)...
BC Extra | Mar 16, 2017
Financial News

Cell Medica raises £60M in series C

Cancer immunotherapy company Cell Medica Ltd. (London, U.K.) raised £60 million ($73.3 million) in a series C round. Existing investors Touchstone Innovations plc (LSE:IVO), Invesco Perpetual and Woodford Investment Management participated. The company's baltaleucel-T ( CMD-003...
BioCentury | Jan 6, 2017
Product Development

Viral vulnerability

Persistent viral infection, even those that are undetectable or asymptomatic, can cause some cancers and contribute to their severity. Viracta Therapeutics Inc. is treating virus-associated cancers by forcing them to re-express latent viral proteins that...
BioCentury | Jul 25, 2016
Product Development

Collecting CAR parts

While CAR T cell therapies have produced impressive response rates in blood cancers, the approach has so far shown limited effect in solid tumors, partly due to poor localization of T cells in tumor sites....
BC Extra | Nov 26, 2014
Top Story

Cell Medica raises L50M series B

Cell therapy developer Cell Medica Ltd. (London, U.K.) raised L50 million ($78.2 million) in a series B round led by Imperial Innovations. Invesco Perpetual and Woodford Investment Management also participated. Cell Medica's CMD-003 ( Cytorex EBV...
BioCentury | Jun 9, 2014
Finance

Imperial coin

Imperial coin On the back of recent successes like the IPO of portfolio company Circassia Pharmaceuticals plc (LSE:CIR), Imperial Innovations Group plc (LSE:IVO) is raising funds to increase its investments in start-ups and support a...
BC Innovations | Oct 24, 2013
Strategy

Driving CAR-based cellular therapies

Adoptive T cell therapies were first developed in the mid-1980s but only recently entered the limelight owing to dramatic clinical results achieved with the latest incarnation, chimeric antigen receptor-based cell therapies. Novartis AG 's 2012...
BC Innovations | Apr 26, 2012
Strategy

Texas translation

The taxpayer-backed Cancer Prevention & Research Institute of Texas is moving downstream from its initial focus on basic research in oncology. This month, the institute announced its latest round of grants-this time focusing on both...
BC Week In Review | Jan 10, 2011
Company News

Cell Medica, Baylor deal

The college granted Cell Medica an exclusive, worldwide license to develop and commercialize its Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) . The product has completed a Phase I/II trial to treat EBV-positive lymphoproliferative disease in...
BC Week In Review | Nov 16, 2009
Clinical News

Epstein-Barr virus: Phase I/II data

In an open-label, U.S. Phase I/II trial, none of the 101 patients who underwent hematopoietic stem cell transplantations and received EBV-specific CTL infusions developed EBV-positive lymphoproliferative disease. Additionally, 11 of 13 patients treated with CTLs...
Items per page:
1 - 10 of 10